New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
10:14 EDTAMGN, BHI, LUFK, KMB, PRI, PDCE, SCHW, CMA, NR, BAS, TS, S, POWI, ELN, ALNY, KEY, LNKD, ESV, GMCR, SIAL, PMC, FOSLOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alnylam (ALNY) downgraded to Hold from Buy at MLV Equity... Charles Schwab (SCHW) downgraded to Sell from Neutral at Citigroup... Elan (ELN) downgraded to Neutral from Buy at UBS... Fossil (FOSL) downgraded to Hold from Buy at Benchmark Co... PDC Energy (PDCE) downgraded to Neutral from Buy at SunTrust... PharMerica (PMC) downgraded to Sector Perform from Outperform at RBC Capital... Power Integrations (POWI) downgraded to Hold from Buy at Deutsche Bank... Primerica (PRI) downgraded to Market Perform from Outperform at Keefe Bruyette... Sigma-Aldrich (SIAL) downgraded to Sell from Neutral at UBS... Sprint (S) downgraded to Neutral from Overweight at Atlantic Equities... Kimberly Clark (KMB) downgraded to Underweight from Equal Weight at Barclays... Green Mountain (GMCR) downgraded to Neutral from Buy at Dougherty... Tenaris (TS) downgraded to Hold from Buy at Dahlman Rose... Lufkin (LUFK) downgraded to Hold from Buy at Dahlman Rose... Ensco (ESV) downgraded to Hold from Buy at Dahlman Rose... Basic Energy (BAS) downgraded to Hold from Buy at Dahlman Rose... Baker Hughes (BHI) downgraded to Hold from Buy at Dahlman Rose... LinkedIn (LNKD) downgraded to Market Perform from Outperform at Northland Securities... Newpark Resources (NR) downgraded to Hold from Buy at Dahlman Rose... Amgen (AMGN) downgraded to Market Perform from Outperform at William Blair... KeyCorp (KEY) downgraded at Stifel Nicolaus... Comerica (CMA) downgraded at Stifel Nicolaus.
News For ALNY;SCHW;FOSL;ELN;PDCE;PMC;POWI;PRI;SIAL;S;KMB;GMCR;TS;LUFK;ESV;BAS;BHI;LNKD;NR;AMGN;KEY;CMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 22, 2015
13:46 EDTBHIBaker Hughes options active on Halliburton antitrust merger concerns
Subscribe for More Information
13:14 EDTBHIBaker Hughes weakness a buying opportunity, says Evercore ISI
Evercore ISI said Baker Hughes (BHI) weakness is a buying opportunity and noted Halliburton (HAL) said it would sell any and all assets to get the deal done, ex-strategic items.
13:03 EDTBHIHalliburton sinks on antitrust concerns after Citi's 90% call
Subscribe for More Information
12:42 EDTBHIHalliburton-Baker Hughes deal to face antitrust hurdle in U.S., Bloomberg says
Subscribe for More Information
12:19 EDTBHIBaker Hughes drops 5% after Bloomberg says DOJ scrutinizing Halliburton deal
Subscribe for More Information
12:17 EDTBHIHalliburton-Baker Hughes deal to face antitrust hurdle in U.S., Bloomberg says
09:35 EDTBHIBaker Hughes results suggest prolong recovery, says Susquehanna
Subscribe for More Information
07:21 EDTSIALThe Protein Society to hold a symposium
Subscribe for More Information
July 21, 2015
16:24 EDTPRIPrimerica says middle-income families to be harmed if DOL's proposal is enacted
Subscribe for More Information
12:47 EDTAMGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:49 EDTAMGNNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
10:01 EDTKMB, GMCROn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:11 EDTBHIBaker Hughes expects North America rig counts to remain unchanged in 2015
Subscribe for More Information
08:10 EDTBHIBaker Hughes reports Q2 North America revenue down 47% to $1.5B
The drop in revenue is primarily attributable to the reduction in customer spending, which has resulted in a steep decline in onshore and shallow water activity, and an unfavorable pricing environment. Reports Q2 Latin America revenue down 19% to $439M, largely result of sharp activity reductions in the Andean area, as reflected in a 43% drop in the rig count, and in Venezuela from decreased operations and unfavorable exchange rates. In Brazil and Mexico, activity reductions were more than offset by offshore share gains. reports Q2 Europe/Africa/Russia Caspian revenue down 22% to $869M, impacted by $100M related to the unfavorable change in foreign exchange rates. Reports Q2 Middle East/Asia Pacific revenue down 22% to $856M, driven primarily by lower activity throughout Asia Pacific, as reflected in the 12% drop in the rig count, and in Iraq as result of a reduction to our integrated operations, including exiting a large turnkey contract in mid-2014. Reports Q2 Industrial Services down 8% to $306M.
08:09 EDTBHIBaker Hughes expects unfavorable market dynamics to persist in 2H15
Subscribe for More Information
08:08 EDTBHIBaker Hughes says Q2 negatively impacted by deteriorating pricing, currency
CEO Martin Craighead commented, "Even though the severity of the revenue decline has compressed our margins, we have minimized the impact by aggressively reducing costs and rightsizing our operational footprint. These actions have resulted in decremental margins of 35% compared to the prior year, a significant improvement from the prior industry downturn. Furthermore, earnings for the quarter were impacted by an unfavorable tax rate which resulted primarily from a change in the geographic mix of earnings."
08:07 EDTBHIBaker Hughes reports Q2 adjusted EPS (14c), consensus (13c)
Subscribe for More Information
07:20 EDTBHIHalliburton has 90% upside potential over 3 years, says Citi
Citi analyst Scott Gruber believes regulatory approval for Halliburton's (HAL) proposed acquisition of Baker Hughes (BHI) is a "high probability event." Halliburton's buyback potential post-acquisition looks significant, Gruber tells investors in a research note. He estimates $5.00 of pro forma earnings per share for Halliburton in 2018, suggesting 90% upside potential for shares over the next three years. The analyst notes that applying a 16 times earnings multiple yields a $78 share price. He keeps a Buy rating on Halliburton with a $54 price target. The oil services company closed yesterday up 75c to $40.74 after reporting Q2 results.
07:12 EDTAMGNAmgen's Repatha granted marketing authorization by EC
Amgen announced that the European Commission, or EC, has granted marketing authorization for Repatha, or evolocumab, the first proprotein convertase subtilisin/kexin type 9, or PCSK9, inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
05:57 EDTGMCRStocks with implied volatility above IV index mean; CMG GMCR
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use